Opinion|Videos|December 4, 2023

Testing for NRG1 Fusions

Author(s)Alexander Spira, MD, PhD, FACP, Joshua K. Sabari, MD

Medical oncologists review testing practices for NRG1 fusions for patients with pulmonary or gastrointestinal malignancies.

Episodes in this series

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 1 Overview of NRG1 Fusions

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 2 NRG1 Fusion Testing Practices

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 3 Recent Data on Zenocutuzumab at ESMO 2023

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 4 Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies

EP. 5 Clinical Pearls on Treating Patients with NRG1 Fusions

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 6 NRG1 Fusions in Lung and GI Cancers

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 7 Testing for NRG1 Fusions

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 8 Clinical Diagnosis of NRG1 Fusions in NSCLC

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 9 Ongoing Research of NRG1-Targeted Therapies

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 10 NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab

Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, experts on non-small cell lung cancer

EP. 11 Key Takeaways for the Treatment of NRG1 Fusion–Positive Malignancies

EP. 12 Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers

EP. 12 Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers

EP. 13 Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma

EP. 13 Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma

Educational support for this activity provided by Merus.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.

October 22nd, 2026

Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC

Helena A. Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC.

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.

October 22nd, 2026

Sunvozertinib Now Available in US for EGFR Exon 20+ NSCLC

Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can now access sunvozertinib.

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

October 20th, 2026

Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.

October 20th, 2026

Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC

The therapeutic cancer vaccine OSE2101 combined with either docetaxel or nivolumab met the primary end point of 1-year overall survival in the Combi-TED trial.

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors: © Sebastian Kaulitzki - stock.adobe.com

October 14th, 2026

VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors

The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.

Trending on CancerNetwork

Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress

INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma

ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC

Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC

Pembrolizumab Plus Chemo Shows Encouraging Activity in NEPC